Q3 EPS Estimates for AngioDynamics Lowered by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at Zacks Research decreased their Q3 2027 earnings per share estimates for AngioDynamics in a note issued to investors on Thursday, April 23rd. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.02 per share for the quarter, down from their previous estimate of $0.03. Zacks Research has a “Hold” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.20) per share.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million.

A number of other research analysts have also recently weighed in on the company. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday. Finally, Canaccord Genuity Group dropped their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Stock Down 0.9%

Shares of ANGO stock opened at $11.10 on Friday. AngioDynamics has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The stock has a market cap of $458.64 million, a P/E ratio of -14.80 and a beta of 0.43. The business has a fifty day simple moving average of $10.82 and a 200-day simple moving average of $11.49.

Institutional Trading of AngioDynamics

A number of large investors have recently made changes to their positions in ANGO. Kotler Kevin acquired a new stake in shares of AngioDynamics during the fourth quarter valued at $21,997,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics during the fourth quarter valued at $17,978,000. UBS Group AG boosted its stake in shares of AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC boosted its stake in shares of AngioDynamics by 28.1% during the third quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after acquiring an additional 393,682 shares during the last quarter. Finally, Nuveen LLC boosted its stake in shares of AngioDynamics by 40.5% during the fourth quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock valued at $16,629,000 after acquiring an additional 373,110 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.